Abstract: The disclosure relates to a safety system for a battery electric vehicle (BEV) that comprises one or more electromotors powered by a battery system, wherein the safety system allows a “limp home mode” to be activated. The disclosure further relates to a battery electric vehicle provided with such a safety system. The battery system of the electric vehicle preferably is the sole power supply of the vehicle for powering the one or more electromotors for a prolonged period of time, e.g. a period of time greater than 10 minutes.

Abstract: Embodiments herein describe a techniques for identifying a first combinational cell 210 in a design for an integrated circuit, identifying a plurality of candidate combinational cells 205 to combine with the first combinational cell using a first criterion. The techniques also include combining the first combinational cell with at least one of the plurality of candidate combinational cells to form a multi-bit (MB) combinational cell 100. Upon determining the MB combinational cell satisfies a performance threshold, the first combinational cell and the at least one of the plurality of candidate combinational cells are replaced with the MB combinational cell in the design.

Abstract: The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The disclosure relates to compounds that act as allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

Abstract: The disclosure relates to a compound of Formula (I), which acts as an allosteric inhibitor of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compound; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

Abstract: In various aspects and embodiments the invention provides a method of treating multiple sclerosis in a subject in need thereof, the method comprising administering to the subject an effective amount of an oligodendrocyte-derived extracellular vesicle.

Abstract: A system receives a logic design of a circuit of an integrated circuit and apply a reduced synthesis process to the logical design of the integrated circuit. The reduced synthesis process is less computation intensive compared to the optimized digital implementation synthesis process and generates a netlist having suboptimal delay. The system provides the generated netlist as input to a timing analysis that alters the standard delay computation (through scaling and other means) to predict the timing of a fully optimized netlist. The reduced synthesis process has faster execution time compared to the optimized digital implementation synthesis process but results in comparable performance, power and area that is within a threshold of the results generated using optimized digital implementation synthesis process.

Abstract: The disclosure relates to compounds that act as an allosteric inhibitors of epidermal growth factor receptor (EGFR); pharmaceutical compositions comprising the compounds; and methods of treating or preventing kinase-mediated disorders, including cancer and other proliferation diseases.

Abstract: A method for operating a battery system with a plurality of cells, a battery system, a vehicle including such a battery system and a computer program element for operating such a battery system. The method for operating a battery system includes monitoring a state of health of each of the plurality of cells, detecting at least one malfunctioning cell, analysing the state of health of the malfunctioning cell, limiting a discharge power over a time period if the malfunctioning cell has a worst state of health in the battery system or limiting a charge power over a time period if the malfunctioning cell has a best state of health in the battery system, and reducing a minimum state of charge of the battery system over the time period.

Abstract: The disclosure relates to a safety system for a battery electric vehicle (BEV) that comprises one or more electromotors powered by a battery system, wherein the safety system allows a “limp home mode” to be activated. The disclosure further relates to a battery electric vehicle provided with such a safety system. The battery system of the electric vehicle preferably is the sole power supply of the vehicle for powering the one or more electromotors for a prolonged period of time, e.g. a period of time greater than 10 minutes.

Abstract: The technology disclosed herein may determine timing windows for speech captions of an audio stream. In one example, the technology may involve accessing audio data comprising a plurality of segments; determining, by a processing device, that one or more of the plurality of segments comprise speech sounds; identifying a time duration for the speech sounds; and providing a user interface element corresponding to the time duration for the speech sounds, wherein the user interface element indicates an estimate of a beginning and ending of the speech sounds and is configured to receive caption text associated with the speech sounds of the audio data.

Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula I: (I), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: (I?), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The application relates to a compound having Formula Ia or Ib: or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The application relates to a compound having Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The application relates to a compound having Formula (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula (Ia) or (Ib): or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a N pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The application relates to a compound having Formula X: (X), wherein: the Targeting Ligand is capable of binding to EGFR, including drug resistant forms of EGFR; the Linker is a group that covalently binds to the Targeting Ligand and the Degron; and the Degron is capable of binding to a ubiquitin ligase, such as an E3 ubiquitin ligase (e.g., cereblon), wherein the Targeting Ligand is of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The application relates to a pharmaceutical combination of an allosteric EGFR inhibitor of Formula Ia or Ib: (Ia) or (Ib), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and an ATP-competitive EGFR inhibitor of Formula I?: (I?), or a pharmaceutically acceptable salt, hydrate, or solvate thereof, which modulates the activity of EGFR, a pharmaceutical composition comprising the combination, and a method of treating or preventing a disease in which EGFR plays a role.

Abstract: The technology disclosed herein may determine timing windows for speech captions of an audio stream. In one example, the technology may involve accessing audio data comprising a plurality of segments; determining, by a processing device, that one or more of the plurality of segments comprise speech sounds; identifying a time duration for the speech sounds; and providing a user interface element corresponding to the time duration for the speech sounds, wherein the user interface element indicates an estimate of a beginning and ending of the speech sounds and is configured to receive caption text associated with the speech sounds of the audio data.

Abstract: An antibody capable of potentiating immune responses and modifying existing states of immune responsiveness is described, as is the sequence of the antibody. Also described are compositions containing the antibody, as well as methods for using the antibody and the compositions to enhance immune responses, to enhance DC function, to modify an existing state of immune responsiveness, to immunize individuals, or to treat or inhibit conditions such as allergic asthma.